The DOI matches its Crossref record; 171 of the 171 references it cites were found in a registry or an index.
Src family kinases in tumor progression and metastasis
Abstract
The Src family of non-receptor protein tyrosine kinases plays critical roles in a variety of cellular signal transduction pathways, regulating such diverse processes as cell division, motility, adhesion, angiogenesis, and survival. Constitutively activated variants of Src family kinases, including the viral oncoproteins v-Src and v-Yes, are capable of inducing malignant transformation of a variety of cell types. Src family kinases, most notably although not exclusively c-Src, are frequently overexpressed and/or aberrantly activated in a variety of epithelial and non-epithelial cancers. Activation is very common in colorectal and breast cancers, and somewhat less frequent in melanomas, ovarian cancer, gastric cancer, head and neck cancers, pancreatic cancer, lung cancer, brain cancers, and blood cancers. Further, the extent of increased Src family activity often correlates with malignant potential and patient survival. Activation of Src family kinases in human cancers may occur through a variety of mechanisms and is frequently a critical event in tumor progression. Exactly how Src family kinases contribute to individual tumors remains to be defined completely, however they appear to be important for multiple aspects of tumor progression, including proliferation, disruption of cell/cell contacts, migration, invasiveness, resistance to apoptosis, and angiogenesis. This review details the evidence for Src family activation in human tumors, and emphasizes possible consequences to tumor progression. Given the ability of Src and its family members to participate in so many aspects of tumor progression and metastasis, Src family kinases are attractive targets for future anti-cancer therapeutics.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“SRC kinase, a cytoplasmic non-receptor tyrosine kinase, has been implicated in the development and progression of cancer [19–22].”
From Co-targeting SRC overcomes resistance to BRAF inhibitors in colorectal cancer (2025) · cites this paper as [22]
In the citing paper
“In addition to MAPK, SRC kinases can directly modulate many downstream targets including and c-MYC [19, 21, 22, 44], related to drug resistance and tumor cell survival.”
From Co-targeting SRC overcomes resistance to BRAF inhibitors in colorectal cancer (2025) · cites this paper as [22]
Citations
Cites
CELLULAR FUNCTIONS REGULATED BY SRC FAMILY KINASES
Thomas, S. Μ., & Brugge, J. S. (1997) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.13.1.513 · Cited by 2,537
Transforming gene product of Rous sarcoma virus phosphorylates tyrosine
Hunter, T. R., & Sefton, B. M. (1980) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.77.3.1311 · Cited by 2,333
Three-dimensional structure of the tyrosine kinase c-Src
Xu, W., Harrison, S. C., & Eck, M. J. (1997) · Nature · doi:10.1038/385595a0 · Cited by 1,432
DNA related to the transforming gene(s) of avian sarcoma viruses is present in normal avian DNA
STEHELIN, D., VARMUS, H. E., BISHOP, J. M., & VOGT, P. K. (1976) · Nature · doi:10.1038/260170a0 · Cited by 1,321 · cited 2×
“Through then very tedious molecular approaches, Bishop and Varmus [3] demonstrated that the viral Src gene (v-src) had as its progenitor a normal cellular gene (proto-oncogene) c-src, an experiment largely responsible for the awarding of the”
BackgroundRegulation, substrates and functions of src
Brown, M. T., & Cooper, J. A. (1996) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/0304-419x(96)00003-0 · Cited by 1,193
Crystal structure of the Src family tyrosine kinase Hck
Sicheri, F., Moarefi, I., & Kuriyan, J. (1997) · Nature · doi:10.1038/385602a0 · Cited by 1,171
A SARCOMA OF THE FOWL TRANSMISSIBLE BY AN AGENT SEPARABLE FROM THE TUMOR CELLS
Rous, P. (1911) · Journal of Experimental Medicine · doi:10.1084/jem.13.4.397 · Cited by 1,051
Tyrosine kinase/p21ras/MAP‐kinase pathway activation by estradiol‐receptor complex in MCF‐7 cells.
Migliaccio, A., Domenico, M. D., Castoria, G., de Falco, A., Bontempo, P., Nola, E., & Auricchio, F. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00471.x · Cited by 950
Identification of a transformation-specific antigen induced by an avian sarcoma virus
Brugge, J. S., & Erikson, R. L. (1977) · Nature · doi:10.1038/269346a0 · Cited by 889
Role of Src expression and activation in human cancer
Irby, R., & Yeatman, T. J. (2000) · Oncogene · doi:10.1038/sj.onc.1203912 · Cited by 878
Cited by
Items 701–800 of 845
Csk-homologous kinase (Chk/Matk): a molecular policeman suppressing cancer formation and progression
Advani, G., Chüeh, A. C., Lim, Y. C., Dhillon, A. S., & Cheng, H. (2015) · Frontiers in Biology · doi:10.1007/s11515-015-1352-4 · Cited by 3
Lund, S. C., Brábek, J., & Hanks, S. K. (2008) · Molecular Carcinogenesis · doi:10.1002/mc.20466 · Cited by 3
Song, Y., Dong, Y., Bai, W., & Ma, X. (2014) · Tumor Biology · doi:10.1007/s13277-014-2167-7 · Cited by 3
Targeted Therapy in Colorectal Cancer
Kopetz, S. (2008) · Humana Press eBooks · doi:10.1007/978-1-60327-424-1_6 · Cited by 3
Cucurbitacin B in cancer: A comprehensive review of its targets and molecular mechanisms
Mi, L., He, T., Lei, D., Lei, D., Su, A., Wei, T., Li, Z., & Wu, W. (2025) · Biochemical Pharmacology · doi:10.1016/j.bcp.2025.117240 · Cited by 5
Li, S., Wang, N., Liu, Y., Ma, H., Xie, K., & Zheng, T. (2025) · Discover Oncology · doi:10.1007/s12672-025-04047-0 · Cited by 2
Sacha, T., Góra‐Tybor, J., & Szmit, S. (2019) · Oncoreview · doi:10.24292/01.or.119210219 · Cited by 3
Molecular perspectives on systemic priming and concomitant immunity in colorectal carcinoma
Ray, S. K., & Mukherjee, S. (2024) · Journal of the Egyptian National Cancer Institute · doi:10.1186/s43046-024-00211-9 · Cited by 2
Molecular Targeted Therapies in Head and Neck Cancer
Gondi, V., Traynor, A. M., & Harari, P. M. (2011) · Springer eBooks · doi:10.1007/978-1-4419-9464-6_20 · Cited by 2
Morgan, J. C., Majors, J. E., & Galileo, D. S. (2005) · Clinical & Experimental Metastasis · doi:10.1007/s10585-005-6930-4 · Cited by 2
Lee, S., Yoo, J. S., Lee, S.-H., Kim, D., Kim, Y., & Kim, Y.-T. (2013) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2013.01.022 · Cited by 2
Parsons, S. J., Pritchard, J. E., Fox, E. M., & Shupnik, M. A. (2011) · Springer eBooks · doi:10.1007/978-1-4614-1764-4_3 · Cited by 2
Yin, A. C., Goldberg, K. H., Mupparapu, A., Retzbach, E. P., Yin, K., Yang, C. F., & Goldberg, G. S. (2016) · Journal of Cancer Biology and Therapeutics · doi:10.18314/gjct.v2i1.93 · Cited by 2
Inhibitors of Tau-Phosphorylating Kinases
Fallacara, A. L., Trist, I. M. L., Schenone, S., & Botta, M. (2017) · Topics in medicinal chemistry · doi:10.1007/7355_2016_17 · Cited by 2
The Prognostic Value of Tyrosine Kinase SRC Expression in Locally Advanced Rectal Cancer
Rühlmann, F., Nietert, M. M., Sprenger, T., Wolff, H. A., Homayounfar, K., Middel, P., Bohnenberger, H., Beißbarth, T., Ghadimi, Β. M., Liersch, T., et al. (2017) · Journal of Cancer · doi:10.7150/jca.16980 · Cited by 2
Gilaberte, Y., & Fernández‐Figueras, M. T. (2021) · Actas Dermo-Sifiliográficas · doi:10.1016/j.adengl.2021.11.010 · Cited by 2
RetractedV-Src delocalizes Aurora B by suppressing Aurora B kinase activity during monopolar cytokinesis.
Ota, R., Watanabe, T., Wazawa, Y., Kuwajima, H., Honda, T., Soeda, S., Saito, Y., Yuki, R., Fukumoto, Y., Yamaguchi, N., et al. (2023) · Cellular Signalling · doi:10.1016/j.cellsig.2023.110764 · Cited by 2
Therapeutic strategy using novel RET/YES1 dual-target inhibitor in lung cancer
Choi, Y. J., Choi, M., Park, J., Park, M., Kim, M. J., Lee, J. S., Oh, S.-J., Lee, Y. J., Shim, W. S., Kim, J. W., et al. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116124 · Cited by 2
Cancer-targeted therapies and radiopharmaceuticals
Rachner, T. D., Jakob, F. J., & Hofbauer, L. C. (2015) · BoneKEy Reports · doi:10.1038/bonekey.2015.76 · Cited by 2
Plakophilin-2 induced EGFR phosphorylation: a focus on the intracellular activators of EGFR
Arimoto, K., Weng, S., & Zhang, D. (2015) · Receptors & Clinical Investigation · doi:10.14800/rci.485 · Cited by 2
Endocrine resistance and breast cancer invasion
Hiscox, S., Gee, J. M. W., & Nicholson, R. I. (2007) · Cancer metastasis · doi:10.1007/978-1-4020-5867-7_7 · Cited by 2
Sawyer, T. K., Bohacek, R. S., Shakespeare, W. C., Metcalf, C. A., Wang, Y., Sundaramoorthi, R., Keenan, T. P., Narula, S. S., & Dalgarno, D. C. (2005) · Springer eBooks · doi:10.1007/0-387-24532-4_11 · Cited by 2
Villemeur, M., Tamaddon, A. M., Bertrand, J., & Malvy, C. (2009) · The Open Nanomedicine Journal · doi:10.2174/1875933500902010036 · Cited by 3
Methylenedioxyanilino-quinazolines and -cyanoquinolines as inhibitors of MEK and/or Src
(2004) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.14.7.1095 · Cited by 2
Rolta, R., Salaria, D., Fadare, O. A., Kaur, G., Fadare, R. Y., Prakash, A., Kaman, L., & Medhi, B. (2025) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2025.152733 · Cited by 1
Recent advances in Pyrazolo[3,4-d]pyrimidine-based dual inhibitors in the treatment of cancers
Jiang, H., Li, N., Qin, R., Lin, S., Wang, X., Li, C., Shen, J., Chen, Y., Liu, J., & Ding, S. (2025) · Molecular Diversity · doi:10.1007/s11030-025-11379-0 · Cited by 1
Ferrarini, M. G., de Marchi, M. S., Moggio, E. L., Brum, H., Kugeratski, F. G., Batista, M., Ribeiro, C. A. D. O., & Ávila, A. R. (2026) · Chemosphere · doi:10.1016/j.chemosphere.2026.144857 · Cited by 1
Madalageri, M., Sadashivanavar, V., Kinnal, R., Atchou, K., & Pai, K. S. R. (2026) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2026.154083 · Cited by 1
Inhibition of the Src Oncogene: Therapeutic Potential in Ovarian Carcinoma
Han, L. Y., & Sood, A. (2011) · Springer eBooks · doi:10.1007/978-1-4419-7216-3_5 · Cited by 1
Genetically Modified Bacteria as Targeted Agent for Cancer
Jin, S., Whang, Y. M., & Chang, I. H. (2016) · Journal of Urologic Oncology · doi:10.22465/kjuo.2016.14.2.54 · Cited by 1
Mucosal Repair and Restitution
Frey, M. R., & Polk, D. B. (2006) · Elsevier eBooks · doi:10.1016/b978-012088394-3/50019-2 · Cited by 1
Genetic Susceptibility Markers of Gastrointestinal Cancer
Kumar, M., & Pola, S. (2020) · Diagnostics and therapeutic advances in GI malignancies · doi:10.1007/978-981-15-4431-6_7 · Cited by 1
Nano drug delivery strategies for the treatment and diagnosis of oral and throat cancers
Perdomo, S. J., Fonseca-Benítez, A. V., Cardona-Mendoza, A., Romero‐Sánchez, C., & Párraga, J. E. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-819793-6.00004-7 · Cited by 1
Molecular Processes Involved in Pancreatic Cancer and Therapeutics
Makar, S., Ghosh, A., divya, D. D., Shivhare, S., Kumar, A., & Singh, S. K. (2020) · Current Chemical Biology · doi:10.2174/2212796814999201008130819 · Cited by 1
Wen, X.-H., Sun, X., Ou, Z., Jiang, J., Chen, Q., He, X., Hu, Z., Qiao, H., Zhou, K., Li, X., et al. (2022) · Acta Biochimica et Biophysica Sinica · doi:10.3724/abbs.2022148 · Cited by 1
The serine protease matriptase inhibits migration and proliferation in multiple myeloma cells
Steiro, I. J., Vandsemb, E. N., Elsaadi, S., Misund, K., Sponaas, A., Børset, M., Abdollahi, P., & Slørdahl, T. S. (2022) · Oncotarget · doi:10.18632/oncotarget.28300 · Cited by 1
Synthetic Migrastatic: A New Class of Anticancer Drug
Gayan, S., Doshi, S., & Dey, T. (2022) · Handbook of Oxidative Stress in Cancer: Therapeutic Aspects · doi:10.1007/978-981-16-5422-0_266 · Cited by 1
Zhang, S., Wang, J., & Zhang, H. (2023) · Medicine · doi:10.1097/md.0000000000035826 · Cited by 1
REGIONAL ANAESTHESIA AND ACUTE PAIN
(2012) · British Journal of Anaesthesia · doi:10.1093/bja/aer489 · Cited by 1
CIP4 and Src in Promoting the Migration and Invasion of Breast Cancers
Pichot, C. S. (2010) · Digital Commons-TMC (Texas Medical Center) · Cited by 1
Adverse Features of Acquired Antihormone Resistance and Their Targeting
Hiscox, S., Jordan, N., Morgan, L., Smith, C. R., Goddard, L., Gee, J., & Nicholson, R. (2009) · Springer eBooks · doi:10.1007/978-1-4020-8526-0_8 · Cited by 1
Pharmacogenomics of Dasatinib (Sprycel™)
Huang, F., & Clark, E. A. (2009) · Wiley eBooks · doi:10.1002/9780470524961.ch15 · Cited by 1
Oct3 and Sox2 Expression in Mammary Carcinoma Cells
Soignier, Y. (2010) · eScholarship (California Digital Library) · Cited by 1
Cross talk between ERα and Src signaling and its relevance to ER status and hormone responsiveness
Sun, J., Zhou, W., Nawaz, Z., & Slingerland, J. (2012) · Springer eBooks · doi:10.1007/978-1-4614-1764-4_4
Clinical Development of Src Family Kinase Inhibitors in Malignant Melanoma
Macpherson, I. R., Jones, R. J., & Evans, T. R. J. (2007) · The Open Cancer Journal · doi:10.2174/1874079000701010009 · Cited by 1
YES, a novel therapeutic target in hepatocellular carcinoma
Lapouge, M., & Meloche, S. (2022) · Molecular & Cellular Oncology · doi:10.1080/23723556.2022.2069993 · Cited by 1
EGFRvIII Expression and Signaling in head and neck squamous cell carcinoma
Wheeler, S. E. (2012) · D-Scholarship@Pitt (University of Pittsburgh) · Cited by 1
Slap restricts oncogenic Src-family kinase signaling to maintain colonic epithelial homeostasisPreprint
Naim, D., HOUHOU, Z., Cauchois, F., Espie, K., Simon, V., Boublik, Y., Vives, F. L., Homayed, Z., Paul, C., Maillard, M., et al. (2026) · eLife · doi:10.7554/elife.110324 · Cited by 1
Rachner, T. D., Jakob, F. J., & Hofbauer, L. C. (2016) · Der Internist · doi:10.1007/s00108-016-0076-0
Src Family Tyrosine Kinase Signaling in Mouse and Human Embryonic Stem Cells
Zhang, X. (2013) · D-Scholarship@Pitt (University of Pittsburgh)
Active transport and CNS delivery of novel tyrosine kinase inhibitors.
Chen, Y. (2009) · University of Minnesota Digital Conservancy (University of Minnesota)
Dumitrescu, T. P. (2009) · D-Scholarship@Pitt (University of Pittsburgh)
Identification of Novel c-Yes Kinase Inhibitors
Ramakrishnan, C. V., Thangakani, A. M., Velmurugan, D., & Gromiha, M. M. (2014) · Lecture notes in computer science · doi:10.1007/978-3-319-09330-7_57
García, E. L. (2008) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)
The Role of c-Src Activation in Prostate Tumor Progression
Gallick, G. E. (2004) · doi:10.21236/ada429162
Self-citationRegulation of Breast Cancer Stem Cell by Tissue Rigidity
Engler, A. J., Yang, J., Wei, S. C., Fattet, L., & Ondeck, M. G. (2014) · Defense Technical Information Center (DTIC) · doi:10.21236/ada609393
SRC (v-src sarcoma (Schmidt-Ruppin A-2) viral oncogene homolog (avian))
Hiscox, S. (2011) · Atlas of Genetics and Cytogenetics in Oncology and Haematology · doi:10.4267/2042/44715
Summy, J. M., Trevino, J. G., Baker, C. H., & Gallick, G. E. (2006) · Suizo · doi:10.2958/suizo.21.381
Self-citationThorpe, L. (2013) · Digital Commons-TMC (Texas Medical Center)
Sepe, L., Cantarella, C., Fioretti, F., & Paolella, G. (2009) · IEEE International Symposium on Medical Measurements and Applications (MeMeA) · doi:10.1109/memea.2009.5167991
Blasco, M. S., & Cid, C. (2006)
Targeting the Tumor Microenvironment With Src
Chung, A. S., & Ferrara, N. (2010)
The role and mechanism of action of BRK in breast cancer progression
Miah, S. (2015) · University Library - University of Saskatchewan (University of Saskatchewan)
Pontillo, C. A. (2012) · Repositorio Digital Institucional de la Universidad de Buenos Aires (Universidad de Buenos Aires)
Mechanism of Hic-5/ARA55 action, a novel stromal-specific nuclear receptor coactivator
Heitzer, M. D. (2005) · D-Scholarship@Pitt (University of Pittsburgh)
Kelley, L. C. (2010) · The Research Repository @ WVU (West Virginia University) · doi:10.33915/etd.3258
Convergance of Cytoskeletal Signaling at p21-Activated Kinases
Gururaj, A. E., & Kumar, R. (2008) · Springer eBooks · doi:10.1007/978-1-4020-8341-9_5
Tsai, P., Lin, Y., Fu, Y., Chang, L., & Lin, S. (2016) · Toxicological & Environmental Chemistry Reviews · doi:10.1080/02772248.2015.1137099
Use of genetically engineered mouse models in preclinical drug development
Creedon, H. (2015) · ERA
STAT3 and Src Signaling in Melanoma
Kujawski, M., Cherryholmes, G. A., Priceman, S. J., & Yu, H. (2011) · Springer eBooks · doi:10.1007/978-1-61779-407-0_7
Abelson Kinase Based Regulation of Tumor Cell Invasion in HNSCC
Hayes, K. E. (2013) · The Research Repository @ WVU (West Virginia University) · doi:10.33915/etd.472
Goltsev, А. М., Луценко, О. Д., Yampolska, K., Ostankov, M. V., & Бондарович, М. О. (2016) · ScienceRise Biological Science · doi:10.15587/2519-8025.2016.72757
Study Of The Egfr, Src And Stat3 Pathway In Pancreatic Cancer
Jaganathan, S. (2010) · Journal of International Crisis and Risk Communication Research
Vojvodic, M. (2010) · TSpace (University of Toronto)
Fyn-Mediated Regulation of Protein Kinase A
Barritt, S. (2017) · ScholarWorks -A service of University of Vermont Libraries (University of Vermont)
The Role of Cadherin-11 and gp130 in Transformation by Activated Src
D'Abreo, C. (2011) · QSpace (Queen's University Library)
Xu, J., Jin, H., Li, J., Zhu, J., Hua, X., Tian, Z., Huang, M., Yang, R., Huang, H., & Huang, C. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/309765
Post-translational myristoylation during cell death
Martin, D. D. O. (2011) · ERA: Education and Research Archive (University of Alberta) · doi:10.7939/r36x2s
FRK cancer-related mutations: Effect on enzymatic activity and cellular processes
MacAusland-Berg, J. (2019) · HARVEST (University of Saskatchewan)
The adaptor protein APPL1 regulates cell migration and adhesion dynamics
Broussard, J. A. (2012)
Investigations into the Interaction between Src Kinase and Wnt Signaling
Tang, P. L. (2009) · Libraries and Cultural Resources (University of Calgary) · doi:10.11575/prism/14854
Тихонова, В. В., Finashutina, Y. P., & Кесаева, Л. А. (2021) · Advances in molecular oncology · doi:10.17650/2313-805x-2021-8-3-44-59
Head and Neck Cancer Metastasis
Laskar, S. G., Agarwal, J. P., Mallick, I., & Dinshaw, K. A. (2011) · Cambridge University Press eBooks · doi:10.1017/cbo9780511976117.030
Synthetic Migrastatic: A New Class of Anticancer Drug
Gayan, S., Doshi, S., & Dey, T. (2022) · Handbook of Oxidative Stress in Cancer: Therapeutic Aspects · doi:10.1007/978-981-16-1247-3_266-1
c-Src Family of Tyrosine Kinases
Sen, B., & Johnson, F. M. (2012) · Springer eBooks · doi:10.1007/978-1-4419-0461-4_54
Chi, Q., Chen, S., & Li, S. (2020) · doi:10.21203/rs.3.rs-23894/v1
c-Src Family of Tyrosine Kinases
Sen, B., & Johnson, F. M. (2017) · Springer eBooks · doi:10.1007/978-3-319-67199-4_54
Lang, L., & Teng, Y. (2022) · Methods in molecular biology · doi:10.1007/978-1-0716-2473-9_2
A negative feedback loop underlies the Warburg effectPreprint
Singh, R., & Jaiswal, A. (2023) · Research Square · doi:10.21203/rs.3.rs-3465493/v1
Luo, Y., Li, T., Long, R., Guo, Q., Wei, L., & Wang, X. (2024) · Pharmacological Research - Modern Chinese Medicine · doi:10.1016/j.prmcm.2024.100381
Iranmehr, Z., Yasavoli‐Sharahi, H., Ghaemi, F., Miri, S. R., & Ebrahimi, M. (2024) · Research Square · doi:10.21203/rs.3.rs-5416147/v1
Irradiation of prostate cancer alters circulating small extracellular vesicle functions
Sayeed, A., Garcia, V., Verrillo, C. E., DeRita, R. M., Hossain, M. N., Krishn, S. R., Sey, S., Shields, C. D., Altieri, A. D., Liu, Q., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-03329-5
Yellarthi, P. K., Muthukrishnan, A., Vaishali, M., Mehta, D. N., & Rao, G. R. R. (2025) · Advances in Human Biology · doi:10.4103/aihb.aihb_147_25
Imipramine Inhibits Osteosarcoma Invasion via Src Inactivation and Caspase‐Dependent Apoptosis
Liu, Y., Fang, C., Hsu, L., Hsu, F., & Hu, M. (2025) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.70761
Nonreceptor Tyrosine Kinases and Their Roles in Cancer
Wiener, J. R., & Gallick, G. E. (2011) · Springer eBooks · doi:10.1007/978-1-4614-1216-8_4
Self-citationStructural and functional characterization of the intrinsically disordered Unique domain of c-Src
Maffei, M. (2014) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)
Metadata
- Authors
- Summy, J. M., & Gallick, G. E.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- Corresponding author
- Gallick, Gary E.
- Venue
- Cancer and Metastasis Reviews
- Published
- 2003-12
- Volume
- 22
- Issue
- 4
- Pages
- 337-358
- ISSN
- 0167-7659 (ISSN-L)
- 1573-7233
- OpenAlex
- W1589166971
- Cited by
- 827
- References
- 171
- Citations by year
- 2026: 15 · 2025: 15 · 2024: 17 · 2023: 17 · 2022: 26 · 2021: 27 · 2020: 26 · 2019: 35 · 2018: 32 · 2017: 28 · 2016: 32 · 2015: 37 · 2014: 64 · 2013: 55 · 2012: 49
- FWCI
- 4.32
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- Locations
- Cancer and Metastasis Reviews (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5r01ca065527-07)
- National Cancer Institute (U54CA090810, 2 R01 CA65527)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Mechanisms and Therapy
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Mechanisms of cancer metastasis
- Keywords
- Src family kinases, Src kinase, non-receptor tyrosine kinase, tumor progression, metastasis, constitutive kinase activation, v-Src, malignant transformation, cell migration and invasion, angiogenesis, apoptosis resistance, cancer therapeutics, colorectal cancer, breast cancer, melanoma, lung cancer
- MeSH terms
- Enzyme Activation, Humans, Neoplasm Metastasis, Neoplasms, Neovascularization, Pathologic, Signal Transduction, Disease Progression, src-Family Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review